Myeloma Research Sees Transformation Following ODAC Support For MRD End Point

In an interview with Targeted Oncology, C. Ola Langren, MD, PhD, discussed the continuing impact of the groundbreaking FDA ODAC vote, the future of the Miami Myeloma MRD Meeting, and how researchers plan to continue expanding the role of MRD in myeloma and other hematologic malignancies.

In April of 2024, the FDA’s Oncology Drugs Advisory Committee (ODAC) unanimously approved the use of minimal residual disease (MRD) as an end point for accelerated approval of multiple myeloma therapies. Since then, trial investigators have rapidly adapted to the new paradigm, and new approvals based on MRD are on the horizon.